RobertA.LafyatisMD

Rheumatology • Pittsburgh, PA

Professor, Medicine, Boston University School of Medicine

Join to view full profile

Dr. Lafyatis is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lafyatis' full profile

Already have an account?

Office
3601 Fifth Avenue
Pittsburgh, PA 15213
Phone+1 412-647-0943

Fax+1 412-647-4050

Education & Training

National Institutes of Health Clinical CenterFellowship, Rheumatology, 1986 - 1989
Wake Forest University Baptist Medical CenterResidency, Internal Medicine, 1984 - 1986
Wake Forest University Baptist Medical CenterInternship, Internal Medicine, 1983 - 1984
University of Cincinnati College of MedicineClass of 1983

Certifications & Licensure

PA State Medical License 2015 - 2024
MA State Medical License 1994 - 2017
NC State Medical License 1985 - 1999
MD State Medical License 1986 - 1992
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Rheumatology

Awards, Honors, & Recognition

Fellow (FACR) American College of Rheumatology

Clinical Trials

Mycophenolate Mofetil in Systemic Sclerosis Start of enrollment: 2006 Mar 01
Completed
Phase 1
Fresolimumab In Systemic Sclerosis Start of enrollment: 2011 Jan 01
Completed
Phase 1
IL1-TRAP, Rilonacept, in Systemic Sclerosis Start of enrollment: 2011 Dec 01
Completed
Phase 1, Phase 2
Dimethyl Fumarate (DMF) in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension Start of enrollment: 2016 Dec 01
Terminated
Phase 1
Safety and Tolerability Study of AVID200 in Pts With Diffuse Cutaneous Systemic Sclerosis Start of enrollment: 2019 Jan 01
Active, not recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

22 citations
Modulation of tissue resident memory T cells by glucocorticoids after acute cellular rejection in lung transplantation.
Mark E Snyder, Kaveh Moghbeli, Anna Bondonese, Andrew Craig, Iulia Popescu
The Journal of Experimental Medicine. 2022-04-04
1652 citations
SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues.
Carly G. K. Ziegler, Samuel J. Allon, Sarah K. Nyquist, Ian M. Mbano, Vincent N. Miao
Cell. 2020-05-28
167 citations
Single-cell Analysis Reveals Fibroblast Heterogeneity and Myofibroblasts in Systemic Sclerosis-Associated Interstitial Lung Disease
Eleanor Valenzi, Melissa Bulik, Tracy Tabib, Christina Morse, John Sembrat
Annals of the Rheumatic Diseases. 2019-10-01

Journal Articles

Skin Gene Expression Is Prognostic for the Trajectory of Skin Disease in Patients with Diffuse Cutaneous Systemic Sclerosis
Robert Lafyatis, Yuqing Zhang, Arthritis & Rheumatology

Press Mentions

Forbius Announces the First Patient Dosed in a Phase 1b Diffuse Cutaneous Systemic Sclerosis Trial of AVID200, a Novel TGF-Beta 1 & 3 InhibitorMarch 4th, 2019
Rapid Skin Improvement Seen After Treating Systemic Sclerosis Patients with FresolimumabJune 22nd, 2015

Grant Support

International Workshop On Scleroderma ResearchNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2012
Rheumatic Diseases Research Core CentersNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2011
Project 1 Biomarkers Of Disease Activity And Progression In Systemic SclerosisNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2011
Niams: CortNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2011
Innate Immunity In Dermal Fibrosis And Systemic SclerosisNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2011
Tenth International Workshop On Scleroderma Research - August 2-6,2008, CambridgeNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2008–2009
Microarray Biomarkers Of Disease Activity And Progression In Systemic SclerosisNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2007–2009
Altered Elastogenesis By TSK Fibrillin-1 And In SSCNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2005–2009
Rituximab Treatment Of SclerodermaNational Center For Research Resources2007
International Workshop For Scleroderma ResearchNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2006
Immune Mediated Alterations In Connective TissueNational Center For Research Resources2006
Rituximab Treatment Of Scleroderma - An OPEN Label, Phase I StudyNational Center For Research Resources2005–2006
SWAP And SR Protein Regulation Of Alternaive SplicingNational Institute Of Arthritis And Musculoskeletal And Skin Diseases1997
Autoimmunity To And MRNA Splicing Regulation By SWAPNational Institute Of Arthritis And Musculoskeletal And Skin Diseases1995–1996